




SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION 	ATTY. DOCKET NO. <b>7933-38</b>	SERIAL NO. <b>09/744,405</b>
	APPLICANT: <b>MICHAEL S. HALPERN et al.</b>	
	FILING DATE <b>January 22, 2001</b>	GROUP <b>1633-1642</b>


## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	4,673,563	06/1987	Berne et al.	424	9	
	AB	5,593,972	01/1997	Weiner et al.	514	44	
	AC	5,656,481	08/1997	Baetge et al.	435	325	
	AD	5,693,522	12/1997	Chada et al.	435	325	
	AE	09/167,322		Halpern et al.			10/7/1998

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AF	0 119 702	09/1984	Europe				
	AG	WO 92/14756	09/1992	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AH	Felgner <i>et al.</i> , "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", <i>Proc. Natl. Acad. Sci. USA</i> , 84: 7413-7417, November 1987
	AI	Kuzumaki <i>et al.</i> , "Transplantation Resistance to a Rous Sarcoma Virus-Induced Tumor in Mice Immunized With v-src Protein", <i>J. Natl. Cancer Inst.</i> , Vol 80, No. 12, August 17, 1988, pp 959-962
	AJ	Fendly <i>et al.</i> , "The Extracellular Domain of HER2/neu Is a potential Immunogen for Active Specific Immunotherapy of Breast Cancer", <i>J. Biol. Response Mod.</i> , Vol. 9, No. 5, October 1990, pp 449-455
	AK	Malone <i>et al.</i> , "Cationic liposome-mediated RNA transfection", <i>Proc. Natl. Acad. Sci. USA</i> , 86: 6077-6081, August 1989
	AL	Temin, "Overview of biological effects of addition of DNA molecules to cells", <i>J. Med. Virol.</i> , 31:13-17, May 1990
	AM	Wisner <i>et al.</i> , Tumor Immunity Generated in the Course of Regression of v-src-Induced Sarcomas", <i>J. Virol.</i> , Vol. 65(12):7020-7024, December 1991
	AN	Halpern <i>et al.</i> , "Immune-Based Resistance to the Formation of v-src-Induced Distal Tumors", <i>Virology</i> 197:480-484, 1993
	AO	Disis <i>et al.</i> , "In Vitro Generation of Human Cytolytic T-Cells Specific for Peptides Derived From the HER-2/neu Protooncogene Protein", <i>Cancer Research</i> , 54:1071-1076, February 15, 1994


EXAMINER 	DATE CONSIDERED <b>3/24/02</b>
---	-----------------------------------

EXAMER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
7933-38SERIAL NO.  
09/744,406

## INFORMATION DISCLOSURE CITATION



APPLICANT:

MICHAEL S. HALPERN et al.

FILING DATE

January 22, 2001

GROUP 1633

1642

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	Taylor <i>et al.</i> , "Major Histocompatibility (B) Complex Control of the Formation of v-src-Induced Metastases", <u>Virology</u> , 205:569-573, 1994
AQ	Plachý <i>et al.</i> "src-specific immunity in inbred chickens bearing v-src DNA- and RSV-induced tumors", <u>Immunogenetics</u> , 40:257-265, 1994
AR	Peoples <i>et al.</i> , "Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide", <u>Proc. Natl. Acad. Sci., USA</u> , 92:432-436, January 1995
AS	Conry <i>et al.</i> , "Characterization of a Messenger RNA Polynucleotide Vaccine Vector", <u>Cancer Res.</u> , Vol. 55:1397-1400, 1 April 1995
AT	McCabe <i>et al.</i> , "Minimal Determinant Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic Antitumor Cytolytic T Lymphocyte Responses", <u>Cancer Research</u> , 55:1741-1747, April 15, 1995
AU	Fenton <i>et al.</i> "Cytotoxic T-cell Response and In Vivo Protection Against Tumor Cells Harboring Activated ras Proto-oncogenes", <u>J. Natl. Cancer Inst.</u> , 85(16):1294-1302, August 18, 1993
AV	Halpern <i>et al.</i> "Endogenous c-src as a determinant of the tumorigenicity of src oncogenes", <u>Proc. Natl. Acad. Sci., USA</u> , 93:824-827, January 23, 1996
AW	Disis <i>et al.</i> , "Existent T-Cell and Antibody Immunity to HER-2/neu Protein in Patients with Breast Cancer", <u>Cancer Research</u> 54:16-20, January 1, 1994
AX	Gelman <i>et al.</i> , "Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains", <u>Oncogene</u> , 8:2995-3004, 1993
AY	Gilbert <i>et al.</i> , "Tolerogenicity of Resting and Activated B Cells", <u>J. Exp. Med.</u> , 179:249-258, 1994
AZ	Fuchs <i>et al.</i> , "B Cells Turn Off Virgin But Not Memory T Cells", <u>Science</u> , 258:1156-1159, 1992
BA	Verma <i>et al.</i> , "Gene therapy - promises, problems and prospects" <u>Nature</u> , 389: 239-242, 1997
BB	Restifo <i>et al.</i> , "Molecular Mechanisms Used by Tumors to Escape Immune Recognition: Immunogenetherapy and the Cell Biology of Major Histocompatibility Complex Class I", <u>J. Immunother.</u> , Vol. 14, 182-190 (1993)
BC	Yasutomi <i>et al.</i> , "A Vaccine-Elicited, Single Viral Epitope-Specific Cytotoxic T Lymphocyte Response Does Not Protect against Intravenous, Cell-Free Simian Immunodeficiency Virus Challenge", <u>J. Virol.</u> , Vol. 69 No. 4 (April 1995), 2279-2284
BD	Marshall, Gene Therapy's Growing Pains, <u>Science</u> . 269:1050-1055, 25 August 1995
BE	Orkin <i>et al.</i> , Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995

EXAMINER

DATE CONSIDERED

3/24/02

EXAM: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line thru citation if in conformance and not considered. Include copy of this form with next communication to applicant.

PHIP/301014/1

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
7933-38SERIAL NO.  
09/744,406

## INFORMATION DISCLOSURE CITATION

APPLICANT:  
MICHAEL S. HALPERN et al.FILING DATE  
January 22, 2001

GROUP 1633

1642

TECH CENTER 16012900

JUL 11 2001

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BF	Friedmann, Overcoming the Obstacles to Gene Therapy, <i>Scientific American</i> , June 1997, 96-101
BG	Huang <i>et al.</i> , "Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens", <i>Science</i> , 264:961-965, 13 May 1994
BH	Céfaï <i>et al.</i> , "Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer", <i>Int. J. Cancer</i> , 83:393-400, 1999

EXAMINER

DATE CONSIDERED

3/24/02

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line  
 10  
 formance and not considered. Include copy of this form with next communication to applicant.

701014/1